Cjc-1295 No Dac + Ipamorelin Coa

Direct Answer: What Is a CJC-1295 No DAC + Ipamorelin COA?

A CJC-1295 No DAC + Ipamorelin Certificate of Analysis (COA) is a lot-specific quality document verifying the identity, purity, and safety parameters of this dual-peptide research blend. Generated via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Liquid Chromatography-Mass Spectrometry (LC-MS) by ISO 17025 accredited labs, it confirms ≥99% purity, correct molecular weight, and sub-threshold endotoxin levels.

When inspecting a lot-specific COA for the combined CJC-1295 No DAC + Ipamorelin research blend, research investigators must verify two distinct chromatographic peaks corresponding to each individual peptide, alongside mass spec confirmation of their target monoisotopic masses. Without transparent COAs issued by independent third-party analytical laboratories, research facilities risk introducing truncated peptide sequences, residual synthesis reagents, or bioburden contaminants into delicate cellular and animal models.

Deciphering the COA: RP-HPLC Purity Analysis for Dual-Peptide Systems

Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) serves as the Gold Standard for quantifying chemical purity and confirming the precise stoichiometry of multi-peptide formulations. In a combined CJC-1295 No DAC (also known as Modified GRF 1-29) and Ipamorelin vial, RP-HPLC utilizes a hydrophobic stationary phase (typically C18 silica) and a gradient mobile phase (water/acetonitrile with 0.1% trifluoroacetic acid) to resolve the distinct chemical structures based on hydrophobicity.

Because CJC-1295 No DAC possesses a 29-amino acid chain (molecular formula C152H252N44O42) and Ipamorelin is a pentapeptide (molecular formula C38H49N9O5), their retention times on an RP-HPLC chromatogram diverge significantly. The COA must display two sharp, baseline-separated analyte peaks with no significant tailing or co-eluting impurites. The integrated area under the curve (AUC) for both peptide peaks combined should account for ≥99.0% of total UV absorbance measured at 214 nm or 220 nm, ensuring that total synthesis impurities, deletion sequences, and deamidation products remain well below strict analytical thresholds.

LC-MS Mass Spectrometry: Molecular Weight and Identity Confirmation

While RP-HPLC confirms relative purity, Liquid Chromatography-Mass Spectrometry (LC-MS) is necessary to confirm molecular identity. A complete COA must include Electrospray Ionization Mass Spectrometry (ESI-MS) spectra displaying the observed mass-to-charge ratios (m/z) matching the theoretical molecular weights of both target compounds.

CJC-1295 No DAC exhibits a theoretical monoisotopic mass of approximately 3367.9 Da, yielding distinct multiply charged ions such as [M+3H]3+ and [M+4H]4+ in positive ESI mode. Conversely, Ipamorelin exhibits a theoretical monoisotopic mass of 711.86 Da, predominantly appearing as single [M+H]+ and double [M+2H]2+ charged species. A verified COA from PX1 Research validates that both molecular species are present in exact stoichiometric proportions without unexpected adducts, oxidized side chains, or incomplete protective group removals.

Endotoxin Testing and Bioburden Protocols (ISO 17025 & LAL Assays)

For preclinical research, particularly in vitro cell culture assays and in vivo rodent models, bacterial endotoxins (lipopolysaccharides) pose a severe confounding variable. Endotoxins induce non-specific inflammatory signaling via Toll-like receptor 4 (TLR4) pathways, skewing cytokine profiles and metabolic data. Therefore, an analytical COA must document quantitative endotoxin testing via the *Limulus* Amebocyte Lysate (LAL) chromogenic assay.

PX1 Research enforces a maximum endotoxin threshold of <0.01 EU/mg across its entire catalog of research peptides. Testing performed in ISO 17025 accredited testing environments guarantees that every lyophilized lot undergoes rigorous bioburden analysis, ensuring zero interference with somatotroph signaling cascades or systemic inflammation markers during experimental trials.

Complementary Receptor Mechanisms: GHRHR and GHS-R1a Co-Activation

CJC-1295 No DAC and Ipamorelin operate via distinct, non-competing receptor pathways within the hypothalamic-pituitary axis, creating a synergistic signal transduction dynamic studied extensively in preclinical models:

1. **Growth Hormone-Releasing Hormone Receptor (GHRHR) Activation:** CJC-1295 No DAC acts as a synthetic GHRH analog. Upon binding GHRHR on anterior pituitary somatotrophs, it activates the Gαs protein subunit, stimulating adenylate cyclase and elevating intracellular cyclic adenosine monophosphate (cAMP). This initiates Protein Kinase A (PKA) signaling, promoting transcription and exocytosis of growth hormone (GH) storage vesicles.

2. **Growth Hormone Secretagogue Receptor (GHS-R1a) Activation:** Ipamorelin acts as a selective ghrelin receptor agonist. It binds GHS-R1a, triggering a Gαq-mediated phosphoinositide cascade that activates Phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This induces intracellular calcium (Ca2+) release from the endoplasmic reticulum, augmenting GH vesicle release.

When co-administered in vitro or in preclinical animal models, simultaneous activation of cAMP/PKA and IP3/Ca2+ signaling pathways generates an amplified, physiological GH pulse larger than the additive total of either peptide evaluated independently. Research investigators interested in deeper mechanistic breakdowns can review our guide on Ipamorelin secretagogue pathways.

Preclinical Research Findings: Sustained GH Pulses and IGF-1 Expression

In preclinical animal studies, CJC-1295 No DAC functions as a modified growth-hormone-releasing hormone that sustains physiological GH release and downstream insulin-like growth factor 1 (IGF-1) levels, providing a valuable model for tissue repair, protein synthesis, and cellular regeneration research.

Unlike native GHRH(1-29), which undergoes rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) at the Ala2 position, CJC-1295 No DAC features amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that increase resistance to serine proteases while retaining high binding affinity for GHRHR. In vivo rodent assays demonstrate that pairing this stabilized GHRH analog with Ipamorelin creates robust somatotropic output without causing receptor desensitization or significantly raising cortisol or prolactin levels—a key advantage over older GHRP molecules. For more details on structural stabilization, explore our analysis on CJC-1295 No DAC vs DAC mechanisms.

Comparative Analysis: CJC-1295 No DAC Blend vs. Alternative Secretagogues

To select the appropriate secretagogue for specific experimental parameters, researchers frequently compare CJC-1295 No DAC blends against single-agent GHRH analogs and alternative ghrelin receptor agonists. The table below outlines key structural and functional parameters across representative compounds:

Evaluating secretagogue combinations requires contrasting short-acting and long-acting moieties. While CJC-1295 with DAC includes a Drug Affinity Complex that covalently binds serum albumin to extend half-life to several days, CJC-1295 No DAC exhibits a half-life of ~30 minutes, allowing researchers to simulate natural episodic GH peaks. When evaluating classic analogs, Sermorelin retains native sequence vulnerability to DPP-IV cleavage, requiring higher molar concentrations in vitro. Furthermore, whereas older ghrelin mimetics like GHRP-2 stimulate non-specific adrenocorticotropic hormone (ACTH) and prolactin release in animal models, Ipamorelin demonstrates high selectivity exclusively for GHS-R1a, isolating somatotroph activation.

Laboratory Reconstitution, Buffer Stability, and Storage Protocols

Maintaining peptide integrity after receiving a verified lot requires strict adherence to laboratory handling standards. Lyophilized dual-peptide vials should be stored at -20°C or -80°C prior to reconstitution to prevent moisture-induced hydrolysis or temperature degradation.

Reconstitution protocols for analytical evaluation typically utilize Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4). Reagent addition should target the inner glass wall of the vial, followed by gentle swirling rather than vigorous vortexing, which can induce physical shear stress and peptide aggregation. Post-reconstitution aliquots should be refrigerated at 2°C to 8°C and evaluated within 21 to 28 days, or flash-frozen in single-use aliquots at -80°C to preserve functional purity. Additional protocol documentation is accessible in the PX1 research library.

Sourcing Standards: USA Manufacturing, Lot Traceability, and Quality Verification

Procuring high-purity peptides for laboratory application demands complete transparency across the supply chain. PX1 Research manufactures all compounds in state-of-the-art, GMP-compliant facilities within the USA, employing automated solid-phase peptide synthesis (SPPS) technology to eliminate human error during sequence elongation.

Every batch undergoes comprehensive testing in an independent ISO 17025 accredited laboratory prior to release. Vials feature distinct lot numbers linked directly to published HPLC/MS COA reports, ensuring full traceability from raw amino acid coupling to final packaging. PX1 Research supports institutional procurement through wholesale lab account options and provides same-day dispatch (Monday through Friday) from fulfillment centers located in California and Arizona.